Farallon Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Farallon Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,000	Closed	-$211K	–	166
2025 Q3	$211K	Sell	7,000 -891,000	-99%	-$26.7M	﹤0.01%	123
2025 Q2	$32.7M	Buy	+898,000	New	+$32.4M	0.14%	62
2024 Q4	–	Sell	-4,000	Closed	-$222K	–	165
2024 Q3	$222K	Sell	4,000 -95,000	-96%	-$4.84M	﹤0.01%	139
2024 Q2	$4.07M	Hold	99,000	–	–	0.02%	94
2024 Q1	$4.62M	Buy	+99,000	New	+$4.67M	0.02%	104

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Farallon Capital Management's RARE Position: Q4 2025 in Review

Farallon Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 7,000 shares — an estimated $211K sold.

Farallon Capital Management first reported a position in RARE in Q1 2024 and held it in 5 quarters. The position peaked at $32.7M in Q2 2025. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Farallon Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Farallon Capital Management sold 7,000 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $211K.
Farallon Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 5 quarters.
Farallon Capital Management's Ultragenyx Pharmaceutical position peaked at $32.7M in Q2 2025.
287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Farallon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.